Click Therapeutics warned that Motivista is not for acute symptoms, active suicide risk, patients under age 18, or those not taking antipsychotics.

Overview Debates Related claims Topics Sources

Childhood trauma leads people to develop psychosis

Sixteen-year-old Elise Sebastian killed herself in 2021 at Essex Partnership University NHS Foundation Trust after hospital staff muted the Oxevision camera monitoring alarm system.

Mental health nursing expert Jill Archibald provided evidence to the Lampard Inquiry that Oxevision cameras can increase patient paranoia and cause some patients to scream at the device.

The proposed FY26 budget restructuring includes a $1 billion funding reduction affecting community mental health centers, suicide prevention, and substance use treatment programs.

The JAMA Network Open study found that people diagnosed with attention-deficit/hyperactivity disorder face a 89% to 90% higher rate of death by suicide compared to individuals without ADHD.

Researchers observed that co-existing mental health conditions like depression, along with emotional regulation and impulse control challenges, may contribute to elevated suicide rates among people with ADHD.

Valdo Calocane was diagnosed with paranoid schizophrenia in 2020, had been sectioned four times under the Mental Health Act, and pleaded guilty to manslaughter on the grounds of diminished responsibility in January 2024

A study of U.S. health data published in Lancet Psychiatry reported that GLP-1 users with schizophrenia and type 2 diabetes were less likely to be admitted to a psychiatric hospital than patients taking other types of diabetes medication

A study of U.S. health records published in Lancet Psychiatry found that patients with both schizophrenia and type 2 diabetes who were prescribed GLP-1 receptor agonists had a 24% lower risk of psychiatric hospital admission than those not taking GLP-1s

Patients with schizophrenia and type 2 diabetes prescribed GLP-1 receptor agonists were 29% less likely to visit an emergency department for a mental health crisis compared to those not taking GLP-1s, according to a Lancet Psychiatry study

The authors of the Lancet Psychiatry study published in October 2026 emphasized that randomized controlled trials are required to confirm whether GLP-1 receptor agonists directly reduce psychiatric acute care needs in patients with schizophrenia

Study authors advised that GLP-1 receptor agonists should not be considered a primary psychiatric treatment or prescribed solely to reduce psychiatric hospital admissions based on current evidence

The UK Medicines and Healthcare products Regulatory Agency announced updated safety warnings for all 28 authorised antidepressants, introducing boxed warnings on suicidal thoughts and behaviours in patient information leaflets

The Commission on Human Medicines review into antidepressant safety was initiated after patients and families raised concerns regarding the communication of suicidal thoughts and persistent sexual dysfunction risks

The Medicines and Healthcare products Regulatory Agency advised healthcare professionals to discuss suicidal risks when starting antidepressants, changing dosages, or conducting routine reviews

Medicines and Healthcare products Regulatory Agency chief safety officer Dr. Alison Cave urged patients not to stop taking antidepressants without first consulting their healthcare professional

The UK Medicines and Healthcare products Regulatory Agency expects all future licensed antidepressants to incorporate updated safety warnings on suicidal thoughts and sexual dysfunction to ensure consistent communication across healthcare settings

The Medicines and Healthcare products Regulatory Agency chief safety officer Dr. Alison Cave stated that antidepressant benefits outweigh risks for the vast majority of patients under clinical supervision

In January 2025, the senior coroner for Gloucestershire issued a prevention of future deaths report following the inquest into the death of Thomas Kingston

The senior coroner for Gloucestershire who investigated Thomas Kingston's death questioned whether risk communication regarding suicide and guidance on switching SSRI medications was adequate when patients experience no benefit or suffer adverse effects